Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Intra-Cellular Therapies向FDA提交了Caplyta®（Lumateperone）作爲輔助療法治療重度抑鬱症的補充新藥申請（Snda）。
